The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial

Sophia Zoungas, John Chalmers, Andre-Pascal Kengne, Avinesh Pillai, Laurent Billot, Bastiaan E De Galan, Michel Marre, Bruce Neal, Stephen Harrap, Neil Poulter, Anushka Patel

Research output: Contribution to journalArticleResearchpeer-review

29 Citations (Scopus)


The aim of these analyses was to examine the efficacy of the intensive gliclazide MR-based glucose lowering regimen used in the ADVANCE trial in lowering the level of glycated haemoglobin (HbA1c). All 11,140 randomised patients were included in analyses of treatment efficacy. Treatment efficacy was also examined in subgroups defined by baseline characteristics and treatments. At the end of 5 years follow-up, the mean HbA1c was reduced from 7.5 at baseline to 6.5 in those on intensive glucose control and to 7.3 in those on standard glucose control. With intensive glucose lowering greater proportions achieved HbA1c levels of <or =7.0 , <or =6.5 and <or =6.0 . With intensive glucose lowering substantial reductions in HbA1c were observed across subgroups defined by baseline age, sex, duration of diabetes, BMI, HbA1c or treatment regimen (p
Original languageEnglish
Pages (from-to)126 - 133
Number of pages8
JournalDiabetes Research and Clinical Practice
Issue number2
Publication statusPublished - 2010

Cite this